Parthenolide enhances the metronomic chemotherapy effect of cyclophosphamide in lung cancer by inhibiting the NF-kB signaling pathway

Figure 5 Influence of parthenolide combined with cyclophosphamide on the immune microenvironment in the transplanted tumor. A: Immunohistochemistry (IHC) staining of transforming growth factor β (TGF-β), IL-6, and tumor necrosis factor α (TNF-a), and the percentage of TGF-β, IL-6, and TNF-a positive cells in different treatment groups were compared; B: A-SMA IHC staining in tumor tissues. Magnification: 200 ×. n = 10; ^aP < 0.05; ^bP < 0.01; ^cP < 0.001; ^dP < 0.0001; NS: Not significant. PTL: Parthenolide; CTX: Cyclophosphamide.